Therapy for thymic epithelial tumors
- 649 Downloads
Thymoma is the most common tumor of the anterior mediastinum. This tumor is associated with unique paraneoplastic syndromes. The rarity of this tumor has somewhat obscured the optimal treatment for this disease. The World Health Organization classification system, which published in 1999, appears to be an advance in our understanding of thymoma. The Masaoka classification is now the most widely accepted and is an excellent predictor of the prognosis of thymoma. Now the International Thymic Malignancy Interest Group is currently engaged in the development of a validated formal TNM classification system for thymic malignancies. The optimal treatment of thymoma is performed according to its clinical stage. Surgery remains the mainstay of treatment for thymic epithelial tumors. Minimally invasive surgery including thoracoscopic surgery and robotic surgery for stage I and II thymomas is increasing now. The value of postoperative radiotherapy in completely resected stage II or III tumors is questionable. As thymomas have a moderate response rate to chemotherapy or radiotherapy, multimodality therapy involving surgery, chemotherapy and radiotherapy appears to increase the rate of complete resection and survival in the advanced (stage III and IV) thymomas.
KeywordsThymoma WHO histologic classification Masaoka’s clinical staging system Postoperative radiotherapy Multimodality therapy
Conflict of interest
All the authors have declared no competing interest.
- 3.Rosai J. Histological typing of tumours of the thymus. In: International histological classification of tumours, 2nd ed. New York: Springer; 1999.Google Scholar
- 4.Shimosato Y, Mukai K, Matsuno Y. Tumors of the mediastinum. In: Silverberg SG, editor. AFIP atlas of tumor pathology, 4th series, fascicle 11. Washington, DC: Armed Forces Institute of Pathology; 2010.Google Scholar
- 5.Shields TW. Thymic tumors. In: Shields TW, editor. Mediastinal surgery. Philadelphia: Lea & Febiger; 1991. p. 153–73.Google Scholar
- 8.Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: WHO classification of tumours, 2nd ed. Lyon: IARC Press; 2004. pp. 145–197.Google Scholar
- 37.Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. A phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004;44:369–79.PubMedCrossRefGoogle Scholar
- 40.Kunitoh H, Tamura T, Shibata T, Takeda K, Katakami N, Nakagawa K, et al. A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer. 2010;103:6–11.PubMedCentralPubMedCrossRefGoogle Scholar
- 43.Mornex F, Resbeut M, Richaud P, Jung GM, Mirabel X, Marchal C, et al. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Int J Radiat Oncol Biol Phys. 1995;32:651–9.PubMedCrossRefGoogle Scholar